No Data
No Data
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Two Is Better Than One in the Alzheimer's Market -- Heard on the Street -- WSJ
By David Wainer If you have a potentially massive market all to yourself, a new competitor is usually bad news -- unless the new rival can help you build out the market. That might be the case for m
ALS Pipeline Suffers a Major Hit as Biogen's Tofersen Fails Phase Iii Trial
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Express News | Biogen Exec Says the Alzheimer's Drug Market "Will Develop Faster With Lilly in Play", but Can't Speculate What's Going to Happen With Donanemab's Label
Express News | Biogen Exec Says LEQEMBI Is Going To Do Very Well Whether A Competitor Will Come Or Not; On Lilly's Experimental Alzheimer's Drug, Says "It Will Help To Grow The Market"